Study of AION-301 for chronic kidney disease
Part of Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests an experimental drug called AION-301 for people with chronic kidney disease (CKD). The goal is to see if it's safe and may help slow kidney decline. It's given by IV infusion and compared to a placebo (inactive infusion).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 35 and 75 years old.
- You have chronic kidney disease stage 3, with a certain level of kidney function and protein in your urine.
- You are already taking standard kidney-protective medications (like ACE inhibitors, ARBs, or SGLT2 inhibitors) at a stable dose for at least 3 months, unless you cannot take them.
- You are not pregnant, planning pregnancy, or breastfeeding, and agree to use effective birth control if applicable.
- You have not had an organ transplant, cancer (except some skin cancers) in the last 5 years, or certain heart conditions.
- You do not have severe obesity (BMI under 35), uncontrolled diabetes (HbA1c below 8.5%), or a history of blood clots.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational drug called HRS-1780 in people with chronic kidney disease. It aims to see if the drug can help slow kidney decline and is safe to use.
This study tests an investigational drug called IGT-303 in people with chronic kidney disease caused by type 2 diabetes. It aims to see if the drug is safe and helpful for slowing kidney damage.
This trial tests a new drug called STL303 for patients with IgA nephropathy, a type of kidney disease where IgA (an antibody) builds up and damages kidneys. The study aims to see if STL303 is safe and can help slow kidney damage in people whose current blood pressure medications alone aren't controlling their protein loss.
This study tests an investigational drug called ALN-ANG3 to see if it can help people with diabetic kidney disease. The drug may reduce kidney damage and slow down the loss of kidney function. If you join, you will get the study drug or a placebo (a dummy shot) and be followed by a study doctor.
This study tests different treatments for people with advanced kidney disease, including those on dialysis or with a kidney transplant. It aims to find better ways to manage the condition and improve outcomes.
This phase 3 trial tests an experimental drug (HRS-5965) for people with IgA nephropathy (a kidney disease). It aims to find out if the drug can help reduce protein in the urine and protect kidney function. To join, you must have had a kidney biopsy showing IgA nephropathy within the past 8 years and have significant protein in your urine despite taking standard treatments.
Hear when a new Chronic Kidney Disease Stage 3 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.